Gregory L. Sousa

Gregory L. Sousa

Auto-generated profile, based on publicly available information

Gregory L. Sousa

The Jackson Laboratory, Bar Harbor, ME 04609

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TJTaylor R. Jay
Taylor R. Jay
CMCrystal M. Miller
Crystal M. Miller
PCPaul J. Cheng
Paul J. Cheng
LGLeah C. Graham
Leah C. Graham
SBShane Bemiller
Shane Bemiller
BLBruce T. Lamb
Bruce T. Lamb
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.

1 April 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GHGareth R. Howell
Gareth R. Howell
DMDanilo G. Macalinao
Danilo G. Macalinao
GSGregory L. Sousa
Gregory L. Sousa
MWMichael Walden
Michael Walden
ISIleana Soto
Ileana Soto
SJSimon W.M. John
Simon W.M. John
Glaucoma is one of the most common neurodegenerative diseases. Despite this, the earliest stages of this complex disease are still unclear. This study was specifically designed to identify early stages of glaucoma in DBA/2J mice. To do this, we used genome-wide expression profiling of optic nerve head and retina and a series of computational methods. Eyes with no detectable glaucoma by conventional assays were grouped into molecularly defined stages of disease using unbiased hierarchical clustering. These stages represent a temporally ordered sequence of glaucoma states. We then determined networks and biological processes that were altered at these early stages. Early-stage expression changes included upregulation of both the complement cascade and the endothelin system, and so we tested the therapeutic value of separately inhibiting them. Mice with a mutation in complement component 1a (C1qa) were protected from glaucoma. Similarly, inhibition of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective against glaucomatous damage. Since endothelin 2 is potently vasoconstrictive and was produced by microglia/macrophages, our data provide what we believe to be a novel link between these cell types and vascular dysfunction in glaucoma. Targeting early molecular events, such as complement and endothelin induction, may provide effective new treatments for human glaucoma.

2 April 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GHGareth R. Howell
Gareth R. Howell
ISIleana Soto
Ileana Soto
XZXianjun Zhu
Xianjun Zhu
MRMargaret Ryan
Margaret Ryan
DMDanilo G. Macalinao
Danilo G. Macalinao
SJSimon W.M. John
Simon W.M. John
Glaucoma is a common ocular disorder that is a leading cause of blindness worldwide. It is characterized by the dysfunction and loss of retinal ganglion cells (RGCs). Although many studies have implicated various molecules in glaucoma, no mechanism has been shown to be responsible for the earliest detectable damage to RGCs and their axons in the optic nerve. Here, we show that the leukocyte transendothelial migration pathway is activated in the optic nerve head at the earliest stages of disease in an inherited mouse model of glaucoma. This resulted in proinflammatory monocytes entering the optic nerve prior to detectable neuronal damage. A 1-time x-ray treatment prevented monocyte entry and subsequent glaucomatous damage. A single x-ray treatment of an individual eye in young mice provided that eye with long-term protection from glaucoma but had no effect on the contralateral eye. Localized radiation treatment prevented detectable neuronal damage and dysfunction in treated eyes, despite the continued presence of other glaucomatous stresses and signaling pathways. Injection of endothelin-2, a damaging mediator produced by the monocytes, into irradiated eyes, combined with the other glaucomatous stresses, restored neural damage with a topography characteristic of glaucoma. Together, these data support a model of glaucomatous damage involving monocyte entry into the optic nerve.

1 May 2009 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
MMMingming Ma
Mingming Ma
EBEleanor K. Bors
Eleanor K. Bors
EDEvelyn S. Dickinson
Evelyn S. Dickinson
MKMolly A. Kwiatkowski
Molly A. Kwiatkowski
GSGregory L. Sousa
Gregory L. Sousa
LLLingjun Li
Lingjun Li

1 April 2008 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
ACAndrew E. Christie
Andrew E. Christie
CCChristopher R. Cashman
Christopher R. Cashman
HBHenry R. Brennan
Henry R. Brennan
MMMingming Ma
Mingming Ma
GSGregory L. Sousa
Gregory L. Sousa
PDPatsy S. Dickinson
Patsy S. Dickinson

1 April 2008 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
MMMingming Ma
Mingming Ma
RCRuibing Chen
Ruibing Chen
GSGregory L. Sousa
Gregory L. Sousa
EBEleanor K. Bors
Eleanor K. Bors
MKMolly A. Kwiatkowski
Molly A. Kwiatkowski
LLLingjun Li
Lingjun Li